For this ALL subtype and in particular for Ph+ B-ALL, mTOR inhibitors are usually given in combination with other signalling cascade drugs or in association with TKI, since the antiproliferative activity of a single mTOR inhibitor is not often effective in overcoming drug-resistance. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.